The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
 
Jason Westin
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Genentech/Roche; Iksuda Therapeutics; Janssen Scientific Affairs; Kite/Gilead; Merck; Monte Rosa Therapeutics; MorphoSys/Incyte; Novartis; Seagen
Research Funding - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Julio C. Chavez
Honoraria - Adaptive Biotechnologies; Lilly
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Adicet Bio; AstraZeneca; BMSi; Cellectar; Genmab; Janssen; Kite/Gilead; Novartis; TeneoBio
Speakers' Bureau - Epizyme
Research Funding - Adaptive Biotechnologies; AstraZeneca; Merck (Inst)
 
Anna Sureda
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Takeda
Speakers' Bureau - Takeda
Travel, Accommodations, Expenses - Kite/Gilead
Other Relationship - Celgene; Gilead Sciences; Roche; Sanofi; Takeda
 
Franck Morschhauser
Honoraria - Chugai/Roche; Eisai; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; epizyme; Genmab; Gilead Sciences; Novartis; Roche/Genentech; SERVIER
 
Bertram Glaß
Employment - Helios Klinikum Berlin-Buch
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Kite, a Gilead Company; Novartis; Roche
Research Funding - RIEMSER; Roche
 
Michael Dickinson
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Gilead Sciences; Janssen; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Genmab; Gilead Sciences; Janssen; Novartis; Roche (I)
Research Funding - Abbvie (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Andrew Davies
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genmab; Incyte; Kite, a Gilead Company; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Genmab; Kite, a Gilead Company; Roche
Research Funding - AstraZeneca; CellCentric; MSD; Roche
Travel, Accommodations, Expenses - Roche
 
Ian W. Flinn
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Century Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); Great Point Partners (Inst); Hutchison MediPharma (Inst); Iksuda Therapeutics (Inst); Innocare (Inst); Janssen (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MorphoSys (Inst); Novartis (Inst); Nurix (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Shanghai Yingli Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Agios (Inst); ArQule (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CALIBR (Inst); Celgene (Inst); City of Hope (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Curis (Inst); Fate Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); Myeloid Therapeutics (Inst); Novartis (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Rhizen Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TCR2 Therapeutics (Inst); Tessa Therapeutics (Inst); TG Therapeutics (Inst); Triact Therapeutics (Inst); Trillium Therapeutics (Inst); Unum Therapeutics (Inst); Verastem (Inst)
 
David G. Maloney
Stock and Other Ownership Interests - A2 Biotherapeutics; NAVAN Technologies
Honoraria - A2 Biotherapeutics; Amgen; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead Company; Legend Biotech; MorphoSys; MustangBio; NAVAN Technologies; Novartis; Pharmacyclics; Umoja Biopharma
Consulting or Advisory Role - A2 Biotherapeutics; Amgen; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead Company; Legend Biotech; MorphoSys; MustangBio; NAVAN Technologies; Novartis; Pharmacyclics; Umoja Biopharma
Research Funding - Celgene; Juno Therapeutics; Kite, a Gilead Company
 
Martine Chamuleau
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Novartis
Research Funding - Abbvie; Gilead Sciences
 
Michael Timothy Tees
No Relationships to Disclose
 
Allen Xue
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Amgen; Biogen; Kite, a Gilead Company
 
Shilpa Shahani
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Speakers' Bureau - Amgen
Other Relationship - Kite, a Gilead Company
 
Olga Nikolajeva
Employment - Biotech Pharmacal; IQVIA; Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Travel, Accommodations, Expenses - Kite, a Gilead Company
 
Janet Kang
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
 
Aida Kaplan
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
 
Marco Andreas Schupp
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Harry Miao
Employment - Kite, a Gilead Company; Takeda
Stock and Other Ownership Interests - Gilead Sciences; Kite, a Gilead Company
 
Elizabeth Shima Rich
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences